A TRIFUNCTIONAL INGREDIENT FOR AN INTEGRAL COLLAGEN TREATMENT
Collagen is the most abundant protein in the skin and the major component of the extracellular matrix (ECM).

- Gives the dermis its mechanical and structural integrity.

A typical collagen molecule has a long, triple-stranded helical structure, in which three collagen polypeptide chains are wound around one another in a rope-like superhelix.
TYPES OF COLLAGEN

FIBRILLAR COLLAGENS: I, II, III, V, XI

- **Type I:**
  - the most abundant collagen in the human body
  - fibrils have a great tensile strength and elastic resistance

- **Type III:**
  - accumulates around blood vessels and is plentiful in fetal skin
  - youthful skin contains a predominance of Collagen III
  - as skin ages type III fibres are replaced by type I fibres

NON-FIBRILLAR COLLAGENS: IV, VI, VII, VIII, IX, X, XII-XIX

- **Type IV:**
  - the most abundant structural component of basement membranes
  - constitutes a stable scaffold for the basal lamina of the DEJ
  - serves as anchoring support for cells and other constituents of the basement membrane
COLLAGEN - FEATURES OF AGED SKIN

a) Reduced Collagen synthesis

b) Increased disorganisation of the fibril network

c) Increased Collagen degradation: increased MMP (matrix metalloproteinases) expression and collagen glycation

UV irradiation accelerates the aging process (photoaging)

Skin loses elasticity

Skin sags and forms furrows

Wrinkle formation
TRYLAGEN® is a combination of active peptides and proteins

- Provides an efficient treatment to restore the collagen levels of both young and mature skin.
- Maintains an adequate long-lasting collagen function that will ensure a healthy and youthful skin

TRYLAGEN® acts on 3 main functions:

- Collagen Boosting
- Collagen Protection
- Collagen Organisation
TRYLAGEN® contains a combination of ingredients that tackle the problems associated with different stages in the collagen cycle and provide an integral treatment to improve overall collagen quality.

**PRODUCTION**
- PSEUDOALTEROMONAS FERMENT EXTRACT
- HYDROLYZED WHEAT PROTEIN
- HYDROLYZED SOY PROTEIN

**ORGANIZATION**
- TRIPEPTIDE-10 CITRULLINE

**PROTECTION**
- HYDROLYZED WHEAT PROTEIN
- HYDROLYZED SOY PROTEIN
- TRIPEPTIDE-1

TRYLAGEN® keeps our skin’s collagen in balance.

This is macroscopically translated in a significant ANTI-WRINKLE EFFECT.
A) COLLAGEN BOOSTING

- As skin ages, collagen synthesis is decreased and degradation is increased, resulting in connective tissue damage, and loss of the skin’s 3D integrity.

- Reduced synthesis of collagen types I and III is characteristic of chronologically aged skin.

TRYLAGEN® boosts the synthesis of Collagens type I, III and IV, helping to increase the levels of collagen lost due to the aging process
1. Increase in Collagen types I and IV synthesis

- A cream containing 1.25% PSEUDOALTEROMONAS FERMENT EXTRACT was tested on a reconstituted human skin model.

128% increase of Collagen I synthesis and 81% increase of Collagen IV synthesis after 15 days

5% TRYLAGEN® contains 0.62% PSEUDOALTEROMONAS FERMENT EXTRACT
2. Increase in Collagen type III synthesis

- Human dermal fibroblasts were treated with a mixture of HYDROLYZED SOY PROTEIN and HYDROLYZED WHEAT PROTEIN at two concentrations for 7 days.

After 7 days, Collagen III production almost tripled at the dose of 0.0125%

5% TRYLAGEN® contains 0.236% of the mixture HYDROLYZED SOY PROTEIN + HYDROLYZED WHEAT PROTEIN
The process of fibrillogenesis results in the formation of collagen bundles that are responsible for the strength and resiliency of the skin.

- Fibrils age-related changes: diameter becomes irregular and distribution is not uniform.
- The disturbance of the aging collagen network has a significant effect on skin suppleness and elasticity.

TRYLAGEN® controls collagen fibril dimensions: it uniformises their diameter and spaces them regularly, providing a better cohesion and stabilisation of fibres.
3. Dermal Collagen fibrils study

- Tissues from a 3D human skin model EFT-200 (MatTek Corporation) were treated with TRIPEPTIDE-10 CITRULLINE 0.01% or non treated (controls)

Control (untreated) vs Treated with TRIPEPTIDE-10 CITRULLINE

Control tissues have irregular fibrils, while tissues treated with TRIPEPTIDE-10 CITRULLINE present more uniform collagen fibrils

5% TRYLAGEN® contains 0.002% TRIPEPTIDE-10 CITRULLINE
GLYCATION INHIBITION

✓ Glycation is a damaging reaction to proteins, increased with aging. It is a non-enzymatic reaction between free amino groups in proteins and reducing sugars such as glucose.
✓ In skin, glycation creates new residues or cross-linking of collagen (Advanced Glycation End products, AGEs).
✓ AGEs increase during intrinsic aging of normal human skin.
✓ Intermolecular cross-linking in aged skin results in the loss of elasticity and the stiffness of tissues observed during aging.

TRYLAGEN® inhibits glycation, avoiding the formation of AGEs, whose accumulation irreversibly induces the loss of skin elasticity.
IN VITRO EFFICACY (IV)

4. Glycation Inhibition

- The samples treated with 0.001% TRIPEPTIDE-1 experienced an increase in SOD activity, which means that TRIPEPTIDE-1 inhibited SOD glycation.

+39 increase in SOD activity was observed with 0.001% TRIPEPTIDE-1
C) COLLAGEN PROTECTION

COLLAGENASE - HUMAN MMPs INHIBITION

✓ Skin aging is associated with increased MMP (matrix-degrading metalloproteinases) expression and enhanced collagen degradation
✓ MMPs are a family of proteolytic enzymes that specifically degrade collagen, elastin and other proteins in connective tissue
✓ Human MMPs:

  **MMP-2**: cleaves type IV collagen and it is also capable of degrading type I collagen
  **MMP-3**: degrades type IV collagen

TRYLAGEN® inhibits the activity of metalloproteinases (MMP-2 and MMP-3), protecting collagen from degradation
5. Human MMPs inhibition activity

- The fluorescence released by quenched gelatin (denatured collagen) when digested with human MMP-2 and MMP-3 was measured.

TRYLAGEN® showed to inhibit human MMP-2 activity by 73.9%, and human MMP-3 activity by 56.6% at the recommended dose of 5%.
TRYLAGEN® acts at 3 different stages in the life of Collagen:

- **synthesis**
- **formation**
- **degradation**

**COLLAGEN ORGANISATION**

**COLLAGEN BOOSTING**

**TRYLAGEN®**

**COLLAGEN PROTECTION**

**WRINKLE REDUCTION**
6. Anti-wrinkle effect

- A panel of 20 female volunteers aged 35 to 55 used a cream containing 5% TRYLAGEN® twice daily during 30 days.
- The volunteers applied a placebo cream on one side of the face (around the eye) and the cream containing TRYLAGEN® on the other side.

After 30 days, a 29% decrease in wrinkle depth was accomplished for the cream containing 5% TRYLAGEN®, with maximum values up to 35.32% decrease.
COSMETIC BENEFITS

TARGET
Women aged 30-60 years

trylagen®

3 actions in 1 product
First product that acts at the three stages in collagen life.

Functional product
Visible results in 28 days

Improves COLLAGEN quality
Strength

Efficacy at 1-5%
DESCRIPTION
Combination of active peptides and proteins that provide an efficient treatment to restore the collagen levels of youth and mature skin, maintaining an adequate long-lasting collagen function that will ensure a healthy and youthful skin.

APPEARANCE
Yellow suspension.

INCI
Water (Aqua), Pseudoalteromonas Ferment Extract, Hydrolized Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1, Lecithin, Xanthan Gum, carbomer, Triethanolamine, Caprylyl Glycol.

PROPERTIES
Integral collagen treatment that tackles the problems associated with each aging stage.

APPLICATIONS
Trylagen can be incorporated in cosmetic formulations where attenuation of wrinkles is desired.

DOSAGE
1-5%
A TRIFUNCTIONAL INGREDIENT FOR AN INTEGRAL COLLAGEN TREATMENT

Disclaimer:
While the claims and supporting data provided in this publication are believed to be reliable and they are presented free and for guidance only, there are no warranties of any kind. All expressed and implied warranties are disclaimed. The recipient is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulations. LIPOTEC is the exclusive holder of the both industrial and intellectual property rights identified herein. Recipient of this publication agrees to indemnify and hold harmless each entity of the LIPOTEC organization for any and all regulatory action arising from recipient’s use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and not present this publication as evidence of finished product claim substantiation to any regulatory authority.